1Craig WA. Pharmacokinetic/Pharmacyodynamic parameters:rationale for antibacterial dosing of mice and men[J]. Clin Infect Dis, 1998,26:1-10.
2Zhanel GG. Influence of pharmacyokinetic and pharmacodynamic Principles on Antibiotic Selection[J]. Curr Infect Dis Rep, 2001,3: 29-34.
3Tulkens PM. New strategies to avoid development of microbial resistance[C]. A symposium on resistance and the use and misuse of antimicrobial therapy, 2000,44-52.
4Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing : from concept to clinic[J]. Int J Antimicrob Agents, 2002,19 : 341-348.
5Prins JM, Speelman P. Once daily aminoglycosides: practical guideline[J]. Neth J Med, 1998,52 : 1-9.
6Hierholzer WJ,Garner JS, Adams AB, et al. Recommendations for preventing the spread of vancomycin resistance:Recommendations of the HICPAC[J]. Am J Infect Control, 1995,23: 87-94.
7HICPAC. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin[J]. Morb Mortal Wkly Rep,2002,51:565-567.
8Schaad UB,Abdus Salam M,Aujard Y,et al. Use of fluoroquinolones in pediatrics : Consensus report of an International Society of Chemotherapy commission[J]. Pediatr Infect Dis J, 1995,14:1-9.
9Schaad UB, Wedgwood J. Lack of quinolone-induced arthropathy in children[J]. J Antimicrob Chemother, 1992,30:414-416.
10Drlica K. The mutant selection window and antimicrobial resistance[J]. J Antimicrob Chemother, 2003,52 : 11-17.
